A novel drug for treatment of diabetic retinopathy

(c) Centenary Institute, Sydney, Australia

Scientists at the Centenary Institute have developed a novel drug which could potentially be used to effectively treat patients with diabetic retinopathy.

Diabetic retinopathy often occurs in diabetic patients, even when their blood sugar levels are controlled. In diabetic retinopathy, the tiny blood vessels in the retina are damaged and can leak fluid or haemorrhage, often leading to vision loss.

New drugs in the pipeline target novel pathways for treatment of diabetic retinopathy

from NEI

There is exciting on-going research in the field of treatments for patients with diabetic macular edema (DME). There is a long list of drugs in the pipeline for treating this disease that affects a significant number of people around the world. Pipeline drugs target novel pathways to treat diabetic eye disease.

FDA approves Ozurdex for diabetic macular edema

Food and Drug Administration (FDA) has approved Allergan's Ozurdex (dexamethasone 0.7 mg, a sustained-release biodegradable intravitreal implant), for the treatment of diabetic macular edema (DME).